IP Library Granted Patent US 9,795,720
Granted Patent B2
US 9,795,720 · App. 15/211,833 · Granted Oct 24, 2017

Coatings with crystallized active agent(s) and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,720
App. No.
15/211,833
Granted
Oct 24, 2017
Kind
B2
Abstract

Aspects herein relate to coatings with crystallized active agent(s) and related methods. A method for coating a medical device herein includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device.

Claims (11)

1. A method for applying an active agent in a coating onto a medical device, the method comprising:

selecting a solvent and a hydrophobic polymer, wherein the polymer and solvent form a true solution;

selecting a concentration of an active agent, wherein the concentration of active agent is at least 80% of saturation in a composition comprising the solvent and about 1.0 to about 99.0 wt. % polymer;

combining the active agent, the polymer, and the solvent to form a coating composition having the selected concentration of the active agent;

applying the coating composition to the medical device; and evaporating the solvent leaving behind crystals of the active agent;

the active agent selected from the group consisting of paclitaxel, rapamycin and rapalogs.

2. The method of claim 1 , the active agent comprising paclitaxel.

3. The method of claim 1 , the active agent comprising rapamycin.

4. The method of claim 1 , the hydrophobic polymer have a solubility parameter of less than about 10.0 (cal/cm 3 ) 1/2 .

5. The method of claim 1 , the hydrophobic polymer comprises a first polymer component comprising at least one poly(alkyl)(meth)acrylate and a second polymer component comprising poly(ethylene-co-vinyl acetate), wherein the second polymer component is selected from the group consisting of poly(ethylene-co-vinyl acetate) polymers having vinyl acetate concentrations of between about 10% and about 50% by weight.

6. The method of claim 1 , wherein the active agent is at least 95% crystallized.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS COATINGS, LLC
Reel/Frame 073928/0178 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →